New Studies Link GLP-1 Drugs Like Semaglutide to Reduced Dementia Risk in Diabetics

Research published in JAMA Neurology highlights a significant association between GLP-1 receptor agonists and lower Alzheimer’s risk, with semaglutide showing particular promise.